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BACKGROUND: Globally, 1 in 11 adults have diabetes mellitus, most of whom are type-2 diabetic 
(T2D). Risk of T2D is influenced by many factors, including diet. The synthesis of long-chain n-6 
polyunsaturated fatty acids (LC n6 PUFAs) has been posited as a risk factor for T2D; however, its 
causal role is uncertain. 
 
AIM: To test the causal effect of LC n-6 PUFA synthesis on insulin resistance and trans-generational 
T2D risk in a large cohort of men and women. 
 
METHODS: Two-sample Mendelian randomisation (MR) was conducted to evaluate the effect of low 
or high levels of LC n6 PUFA synthesis on glycaemia and development of T2D in the UK Biobank 
(n=463,010) and MAGIC (n=5,130) cohorts. Increased likelihood of predisposition to low or high LC n6 
PUFA synthesis and risk of T2D was also investigated using participant’s siblings and parents. In MR-
base, four genetic variants associated with LC n6 PUFA synthesis (P<10-8). After pruning, one variant 
(rs174547) on the FADS1 gene was retained. 
 
RESULTS: Lower LC n6 PUFA synthesis and abundance (per % unit decrease) is associated with small 
reductions in the insulin disposition index (-0.038 ± 0.012; P=0.002) within MAGIC. In UK Biobank, we 
report negligible effects of low n6 PUFA synthesis on odds of T2D (OR < 1%; P<0.05). Additionally, 
reduced LC n6 PUFA synthesis does not appear to be a contributor to familial T2D risk. No significant 
association was observed between LC n6 PUFA synthesis and BMI.  
 
CONCLUSION: In a primarily white European population, LC n6 PUFA synthesis is not a major 
contributor to type-2 diabetes risk. 
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INTRODUCTION 
Globally, nearly 1 in 11 adults are diabetic, of whom 90% have type-2 diabetes (T2D). T2D is 
characterised by a deterioration of β-cell function, often preceded by insulin resistance[1]. A number 
of mechanisms underlying β-cell dysfunction have been proposed, including genetics, bodyweight and 
adiposity, smoking, inflammation, physical activity, and diet.[2-5] 
 
Dietary fats have been positioned as an important risk factor for T2D, with polyunsaturated fatty acids 
(PUFAs) demonstrating a strong association with glucose metabolism[6]. A meta-analysis of 102 
clinical trials (n=4,220 adults) reported that isocaloric replacement of carbohydrates with PUFAs, 
improved measure of glycemia (-0.11 HbA1c %; 95% CI: -0.17, -0.05; -1.6 pmol/L fasting insulin; 95% 
CI: -2.8, -0.4) and insulin secretion (+0.5 pmol/L/min; 95% CI: 0.2, 0.8) more significantly than 
replacement with saturated (SFAs) or monounsaturated (MUFAs).[6] Observational studies have 
reported similar results and estimated that low dietary PUFA consumption may be responsible for up 
to 20% (Population Attributable Fraction, PAF) of T2D cases[7]. However, heterogeneity between 
studies, insufficient power, and confounding[8-10] limit our interpretation of these results. 
 
Of particular interest is the rate of synthesis and abundance of long-chain n-6 PUFAs (LC n6 PUFAs), 
namely arachidonic acid (ARA; 20:4 n6), from shorter precursor n-6 PUFAs, such as linoleic acid (LA; 
18:2 n6) (  1). Although the specific mechanisms remain elusive, it has been observed that exposure 
of primary β-cell cultures to elevated levels of ARA by (i) exogenous application or (ii) impeding the 
conversion of ARA to eicosanoids, stimulates insulin secretion from human islets,[11, 12] suggesting 
that the  metabolism and abundance of LC n-6 PUFAs has a direct effect on insulin secretion. 
Moreover, a nested case-control study (n=2,787, with 673 cases of T2D) within the European 
Prospective Investigation into Cancer and Nutrition (EPIC)-Postdam cohort reported that higher rates 
of  ARA synthesis resulted in a 54% reduction in risk of T2D (RR=0.46; 0.31, 0.70; P-trend<0.0001) 
compared to lowest quintile, in their fully adjusted model.[13] Collectively, this suggests that LC n6 
PUFAs are associated with risk of T2D and may be driven by ARA acting on β-cell insulin secretion; 
however, such studies are limited by confounding. Where confounding is the uncertainty introduced 
by inaccurate or unaccounted variables (e.g., cooking method)[14, 15] that are linked to both the 
exposure (i.e., ARA) and outcome (i.e., β-cell insulin secretion).[16] 
 
To overcome the effects of confounding and provide evidence of a causal association, EPIC elected to 
use a Mendelian randomisation (MR) approach. Briefly, MR uses genetic variants associated with an 
exposure as surrogate measures of that exposure (i.e., instrumental variables). The use of genetic 
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variants (e.g., single nucleotide polymorphisms; SNPs) permits the inference of causality between 
these exposures and outcome because genetic variants are (i) randomly assorted at meiotic 
segregation and (ii) assigned at conception. In a way, this model resembles a life-long randomised 
controlled trial, where the exposures and confounders (e.g., fish intake, fish oil supplementation, 
physical activity, household income) are also randomly distributed.[16, 17] The aim was for the MR 
analysis undertaken by EPIC study to demonstrate a causally protective effect of ARA on T2D[13]. 
However, the wide confidence intervals (RR = 0.98; 95% CI: 0.70, 1.37) they attained suggested that if 
an association exists, a larger sample would be needed to reflect the true causal association between 
n6 PUFA synthesis and T2D. Two-sample MR[18] harnesses summary association results from non-
overlapping groups of individuals to estimate novel causal effects. This method increases the utility of 
large cohorts for MR studies because researchers are not reliant on a single cohort to provide 
exposure and outcome data; in two-sample MR any two independent cohorts may be used ‒ one to 
summarise the genetic variant-exposure association and another to summarise the genetic variant-
outcome association. With this methodology and access to large cohorts with suitable genetic or 
exposure data, this approach can greatly increase statistical power. 
 
To build on previous evidence, we propose the use of two-sample MR to assess the causal association 
between LC n6 PUFA synthesis and risk of T2D. 
 
METHODS 
Instrumental Variables. We performed 2-sample Mendelian randomisation using MR-Base[19] with 
summary data from publicly available GWAS databases ( ). All studies and 
consortia accessed in the present study on MR-Base were approved by their respective ethics 
committee, and the subjects from all the cohorts provided written informed consent.[20-24] 
 
Sample 1. With MR-Base[19], instrumental variables (single nucleotide polymorphisms; SNPs) 
associated (P<5×10−8) with plasma levels (% total fatty acids) of ARA were identified. From the 
Cohorts for Heart and Aging Research in Genomic Epidemiology Consortium (CHARGE; n=8,631 white 
Europeans; 55% women)[25] ‒ comprising the  Atherosclerosis Risk in Communities (ARIC), Coronary 
Artery Risk Development in Young Adults (CARDIA), Cardiovascular Health Study (CHS), Invecchiare in 
Chianti (InCHIANTI), and Multi-Ethnic Study of Atherosclerosis (MESA) ‒ four SNPs were identified: 
rs174547, rs102275, rs1741, and rs16829840. From a nested-case-control study of myocardial 
infarction within the Singapore Chinese Health Study (SCHS; n= 1540) two SNPs were identified: 
rs174577 and rs174548.  Of the 6 SNPs identified, two were removed because their biological 
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function and mechanism of association with ARA were unknown, which risks violation of MR (i.e., no 
horizontal pleiotropy between SNP and outcome): rs1741,  a non-coding intron variant strongly 
associated with vitamin B6–dependent decarboxylase (it is unknown if this variant alters carboxylase 
expression); and rs16829840, a non-coding transcript variant of transmembrane protein (TMEM39A) 
with an uncertain function and cellular location.[26]. Therefore, only four SNPs (rs174547, rs102275, 
rs174577, and rs174548) progressed forward and were evaluated for inclusion in 2-sample MR. 
 
Sample 2. Using previously published data within MR-Base, summary associations for each of the four 
SNPs were obtained for: (i) insulin disposition index in the Meta-Analysis of Glucose- and Insulin-
related traits Consortium (MAGIC; white European men and women; n=5,130); and (ii) self-reported 
diagnosis of T2D  in the UK Biobank (95% white European men and women, n=463,010). The 
disposition index (DI), calculated following an oral glucose tolerance test, is associated with beta-cell 
function (P<0.001) and is a predictor of future T2D (Area Under the Curve = 0.86; 95% CI: 0.82, 
0.89)[27], whereby a lower or reduction in a person’s DI is associated with a shift from normal glucose 
tolerance to impaired glucose metabolism and increased risk of T2D.  
 
In case a SNP was not present in MAGIC or UK Biobank, a proxy SNP in high linkage disequilibrium 
(r2≥0.80) would be identified; however, proxy SNPs were not required as all SNPs were in both 
databases. Palindromic SNPs were permitted with a minor allele frequency (MAF) threshold of 0.30, 
to allow for a high degree of confidence that Sample 1 and Sample 2 datasets were coded in the same 
direction.[28] SNPs were tested for independence and clumped (r2<0.001). Using MR-Base and the 
ld_matrix function (TwoSampleMR) in R (v.3.5.1), we observed LDs with R2 > 0.92 between SNPs 
within the 1000 Genome project of European samples. As depicted in Figure 1, the genes/enzymes 
for elongation and desaturation are shared by the n6 and n3 pathways; therefore, a single SNP may 
be associated with multiple PUFAs. To negotiate this link, we used existing summary data[25] to 
confirm that our instrumental variable (rs174547) explained a very high degree of variation of n6 
PUFAs levels and, comparatively, little variation of n3 PUFA levels. While the effect of rs174547 is 
significant across numerous PUFAs, the magnitude of effect of rs174547 on n6 PUFAs is significantly 
greater (up to 22-fold more)[29], suggesting that rs174547 is primarily a regulator of n6 PUFA 
synthesis. Underlying this association is the large pool of linoleic acid (LA), a short chain n6 PUFA, 
which constitutes ≈90% of all dietary PUFA  and precursor of endogenously synthesized long-chain n6 
PUFA.[30]  Furthermore, as shown in Table 1, we see that while rs174547 may not be an ideal 
instrumental variable for a single n6 PUFA, that it is most strongly associated with n6 PUFAs at 
opposite ends of the pathway and in opposite directions — i.e., higher levels of linoleic acid (an 
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essential short-chain n6 PUFA; β = +1.47 (0.05) % total fatty acids, P-value=5.0×10−274) and lower 
levels of arachidonic acid (a major LC n6 PUFA and precursor of eicosanoids; β =−1.69 (0.02) % total 
fatty acids, P-value 3.0×10−971). Therefore, we have used rs174547 as an instrumental variable of n6 
PUFA synthesis and report all MR associations per 1 % unit decrease of arachidonic acid of total 
plasma fatty acids (i.e. lower n6 PUFA synthesis). This genetic variant demonstrates no association 
with common confounders of diabetes, such as self-reported ‘smoking’ or ‘alcohol intake’ in the UK 
Biobank.[31] In summary, rs174547 meets the three assumptions  of MR[32], it is: (i) correlated with 
the study exposure (n6 PUFA synthesis); (ii) presents no association with other confounding factors 
(i.e., smoking and alcohol), and (iii) offers no alternative independent biological pathway to modify 
the outcome (i.e., only via n6 PUFA synthesis). 
 
Within UK Biobank, we also performed an exploratory analysis of family history of T2D. Briefly, given 
that at least one parent of any individual carrying the risk allele (T) of the rs174547 SNP must also 
carry the same risk allele, then it can be expected that the effect of the SNP on n6 PUFA synthesis and 
T2D risk must also be observed in at least one parent. Further, we expect siblings of a participants 
that carry the rs174547 risk allele to also be more likely this allele and present association between 
n6 PUFA and T2D risk. Data distinguishing between full and half siblings was not available. 
 
Finally, to test whether an association between n6 PUFA synthesis and T2D is mediated by changes in 
adiposity, we also investigated whether n6 PUFA synthesis was causally associated with BMI in men 
and women within the GIANT consortium (n=322,154). 
 
Statistical Methods. Gathering our exposure (sample 1) and outcome (sample 2) summary results was 
the first step towards calculating 2-sample Mendelian randomisation estimates of n6 PUFA synthesis 
on dysglycemia or odds of T2D. In the present study, the online tool mRnd 
(http://cnsgenomics.com/shiny/mRnd/)[33] estimated study power to be over 90% and an F-statistic 
> 11 to detect a significant difference (P<0.05) in risk of T2D of 5%, assuming a conservative mean r2 
of 0.20 between our instrumental variable and exposure and a proportion of T2D in UK Biobank of at 
least 5%.[34] 
 
With a genetic instrument comprised of one SNP, the estimator for assessing a causal association 
between reduced n6 PUFA synthesis and dysglycemia or T2D is the Wald estimate.[35](  2) This 
procedure relies on a relatively simple mathematical equation to calculate the causal effect of the 
exposure on the outcome. In line with the assumptions of Mendelian randomisation, the effect of βGE 
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(i.e., difference in n6 PUFA synthesis due to genetics/SNPs) and βEO (the effect of genetically-
mediated n6 PUFA synthesis on dysglycemia or T2D) are essentially free of confounding (due to 
random assortment of alleles at meiosis and conception) and horizontal pleiotropy. Therefore, βGO 
(the direct effect of the SNPs on dysglycemia or T2D) is simply the product of the βGE and βEO (βGO = 
βGE ! βEO). Having already collected the estimates of βGE and βGO from summary data above, the 
equation can be rearranged to solve for βEO, our primary research question, the causal association 
between n6 PUFA synthesis and dysglycemia or T2D. Results were  calculated per SD change in ARA 
but converted to percent unit change (i.e., 1%) for easier interpretation. 
 
RESULTS 
MR results are shown in Table 2.  Firstly, the MAGIC cohort, we report a small but significant 
association between a 1% reduction of n6 PUFA synthesis and the insulin disposition index (DI) (-
0.038 mM-1; P=0.002). Secondly, within UK Biobank, we report very small but significant associations 
between a 1% reduction of n6 PUFA synthesis and odds of T2D in participants (OR = 1.001; 95% CI: 
1.000, 1.001; P=0.049). Thirdly, in or exploratory analysis of familial risk of T2D, we report that 
mothers of individuals with reduced n6 PUFA synthesis are only more likely to have been T2D by the 
smallest of margins (OR=1.001; 95% CI: 1.000, 1.002; P = 0.042) but not their fathers or siblings.  
 
In our previous work, we observed reductions of n6 PUFA synthesis of ≈1.7% following a 3-month 
supplementation of fish oils (2 g eicosapentaenoic acid and 1 g docosahexaenoic acid) in young and 
older men.[36] Therefore, we also present estimates of effect sizes which are proportional to a 1.7% 
reduction of n6 PUFA synthesis. For DI, this equates to a reduction of -0.0665 (0.021) mM-1. Put into 
context, where an increase of 1 unit of DI is associated with a 60% lower odds of developing T2D 
within 10 years (OR = 0.40; 95% CI: 0.25, 0.66; P<0.001)[27], a reduction -0.0665 mM-1 associates with 
a 6% increased risk of T2D within 10 years. For diagnosis of T2D, the difference in effect sizes 
between a 1% (log OR1% = 0.0005) and a 1.7% reduction in n6 PUFA synthesis are negligible (log OR1.7% 
= 0.00095). Put into perspective, within the UK Biobank where a high proportion habitual fish oil 
intake was reported  (31.2%)[37], we estimate that fewer than 0.03% of cases of T2D may be 
attributed to fish oil supplementation (population attributable risk, PAR). 
Finally, our MR model did not report a significant association between n6 PUFA synthesis and BMI 
(P=0.449) within the GIANT consortium. 
DISCUSSION 
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Using a 2-sample MR approach, we report that a reduction in n6 PUFA synthesis is associated with 
T2D risk but that its effect is trivial. Additionally, we report that n6 PUFA synthesis is not a major 
contributor to family history of T2D. 
 
With the relatively recent application of MR, the majority of analyses investigating the association 
between n6 PUFA synthesis (or ARA abundance) and risk of T2D has been undertaken in large 
cohorts. Most recently, the Multi-Ethnic Study of Atherosclerosis (MESA) cohort (n = 6,282) reported 
an inverse association between ARA levels and fasting insulin (−0.272 per SD, p < 0.001) and HOMA-IR 
(−0.125 per SD, p = 0.03)[38] which agree with our findings and point towards a protective effect 
between ARA and T2D risk. However, our results disagree with a recent MR study that reported a 
small but positive causal association between ARA and T2D risk (1.03; 95% CI: 1.02, 1.05; 
p = 2.51 × 10−5) within the DIAGRAM consortium.[38] As we both used comparable genetic summary 
statistics for estimating ARA levels, this may be an effect of population stratification, influenced by 
small differences in ethnic and geographic allele frequencies between the UK Biobank (multi-ethnic 
from UK) and DIAGRAM (white European from UK, Finland, and US). 
 
The primary aim of this study was to build on the results of a 1-sample MR study performed within 
the EPIC cohort 10 years ago,[13] predating the introduction of 2-sample MR.[18] The EPIC 
population consisted of 2,653 men and women with genetic data related to SNP rs174546 as an 
instrumental variable of n6 PUFA synthesis (rather than rs174547 as we have). The r2 between 
rs174546 and rs174547 is 1.0,[39] suggesting perfect linkage disequilibrium and that MRs performed 
with either SNP should provide equivalent estimates. EPIC reported a risk ratio of 0.98 with wide 
confidence intervals (0.70, 1.37), suggesting low power despite the use of a strong instrumental 
variable (i.e., F-statistic > 10).[16] This is the strength of 2-sample MR, whereby a robust instrumental 
variable identified in one cohort is applied to a second (often larger) cohort with genetic-outcome 
data to improve power. We have taken this approach and report that our results fall within the 
confidence intervals of EPIC and now provide a more accurate representation of the negligible effect 
of n6 PUFA synthesis on T2D risk.  
 
Recent estimates from the DISCOTWIN Consortium (n=34,166 twin pairs) estimate heritability of T2D 
to be 72% (95% CI: 61-78%).[40] Building on this, a GWAS of 69,142 Icelandic men and women  
demonstrated that, within a panel of 36 genetic variants associated with blood glucose, more than 
half were to some degree linked with familial heritability of fasting glucose. The FADS1 variant 
rs174576, strongly correlated with rs174547 (r2 = 0.94), was investigated and showed a small but not 
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significant effect (P=0.069) on heritability of fasting glucose.[41] As an exploratory assessment, we 
investigated if parents and siblings of individuals who carry a genetic predisposition to lowered n6 
PUFA synthesis are also at increased risk of T2D.  Our analysis of parents of siblings suggests that rate 
of n6 PUFA synthesis is not an important or impactful contributor to familial risk of T2D and familial 
risk is driven by other genetic and environmental factors. 
 
The pathway by which n6 PUFA affects glucose levels and diabetes risk is not well-characterised but is 
commonly linked to high adiposity and circulating pro-inflammatory eicosanoids. Indeed, circulating 
levels of n6 PUFA have been associated with increased BMI across the lifespan[42, 43] and elevated 
levels of proinflammatory eicosanoids in unhealthy and healthy humans.[44, 45] Recently, two 
independent MR studies, one using UK Biobank (13,982 T2D cases and 273,412 controls) and the 
other using both the Wellcome Trust Case Control Consortium and Australian adult and adolescent 
cohort (22,669 T2D cases and 58,119 controls) confirmed a causative association between elevated 
BMI and risk of type 2 diabetes:  OR = 1.37 (95% CI: 1.12, 1.68) per kg/m2 increase or OR = 1.47 (95% 
CI: 1.17, 1.85) per 5 kg increase.[46, 47] Unfortunately, instrumental variables of proinflammatory 
eicosanoids have not been identified that are independent of PUFA levels so the causative association 
of proinflammatory eicosanoids on T2D is less well established. Therefore, we sought to investigate 
whether the effects of n6 PUFA levels on T2D were driven by the effects of n6 PUFA on adiposity. Our 
results were not significant and suggest that BMI and n6 PUFA associate with T2D through 
independent pathways. 
 
The strength of MR is in its ability to minimise the effects of confounding; however, as with all studies, 
we cannot rule out the possible effects of unmeasured or latent confounders. Although our 
instrumental variable explained a very high proportion of variation of blood LA and ARA levels, we are 
unable to tease apart or isolate the effects of distinct PUFAs using instrumental variables. However, 
by accepting this limitation and focussing on (i) the causative association of n6 PUFA synthesis on T2D 
and (ii) selecting genetic variants that are more influential towards n6 (rather than n3) PUFA synthesis 
we aimed to minimise this. We also tested our instrumental variable against the pleiotropic effect of 
BMI and found no association. Perhaps the greatest strength of the present study was the very large 
population, which allowed us to very precisely quantify the very small magnitude of effect of n6 
PUFAs on T2D. 
 
CONCLUSION 
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Evidence suggests that any heritable causal association between reduced LC n6 PUFA synthesis and 
impaired glucose metabolism and progression towards type-2 diabetes that does exist in a primarily 
white European population is negligible and likely of little importance in a clinical setting. 
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FIGURE LEGENDS 
 
Fig 1. . Long-chain n6 and n3 PUFAs can be 
synthesized from precursor PUFAs (LA or ALA) by alternating reactions of desaturation and 
elongation. Desaturation is driven by delta-6 and delta-5 desaturase (D5D and D6D), coded by fatty 
acid desaturase (FADS1 or FADS2), while elongation is driven by Elongase, coded by elongation 2 or 5 
(ELOVL 2 or ELOVL 5).  
 
 
Fig 2. . The three points of the triangle represent: Genetic variants (SNPs) associated 
with our exposure and outcome: Exposure of interest, and Outcome of interest. As such the three 
sides of the triangle represent: βGE, the association between specific SNPs and the exposure; βGO, the 
association between specific SNPs and the outcome; and βEO, the association between the exposure 
and the outcome. The Wald ratio states that if βGE and βEO are free of confounding, then their product 
is equal to βGO. Therefore, by rearranging this equation, βEO, the unconfounded association between 
n6 PUFA and dysglycemia and T2D can be investigated. 
